Aesculap AG Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Kelayres PA United States (1977)
Status: No NME R&D (1977)

Organization Overview

First Clinical Trial
2010
NCT00918619
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aesculap AG | Aesculap Biologics, LLC | Aesculape CRO Belgium BV | Aesculap Implant Systems

Active Ingredients

Drugs in Phase 4 Trials (1)

human fibrin (1 trial)

Drugs in Phase 3 Trials (2)

autologous culture chondrocytes (Carticel) (2 trials)

novocart 3d (1 trial)

Drugs in Phase 2 Trials (2)

domiphen hydroxide (1 trial)

miconazole (monistat) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cartilage Diseases (Phase 3)

Fractures, Stress (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5